A key driver of the pharma automation shift is reducing contamination risk and ensuring regulatory compliance by enabling safer, more reliable aseptic processes through automation and AI integration.

Robotics are gaining early traction in robotic tub handling, a practical entry point for automating labor-intensive tasks in pharma manufacturing.

FANUC emphasizes helping companies connect with experienced integration partners and using digital twin and virtual commissioning tools to speed up implementation.

Some firms build in‑house automation capabilities, running experiments in lab settings to define use cases and requirements before engaging integrators for full deployment.

AI today mainly supports visual inspection to detect subtle anomalies and conducts predictive maintenance by monitoring telemetry like force and torque across robotic axes to keep lines running.

Matt Charles of FANUC America is scheduled to discuss these themes in MD&M Midwest’s session, From Cleanroom to Smart Factory: Robotics + AI Patterns for Pharmaceutical Manufacturing, on October 29, 2026, in Room 101E.

New automation efforts face regulatory and design challenges, as processes were historically human-performed and must withstand aggressive cleaning methods without degrading coatings.

Validation remains the main hurdle to scaling automation in regulated settings, with AI models' nondeterminism pushing firms toward locked-down solutions for compliance and reproducibility.

The adoption of robotics and AI in pharma is accelerating amid a robust investment outlook, with an anticipated multi-hundred-billion-dollar drive through 2030 to boost production capacity and quality.

Guidance advocates starting with lower-risk automation projects to gradually build expertise before tackling high-risk aseptic environments.